Overview

Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina

Status:
Suspended

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if veliflapon (DG-031)can prevent a heart attack or stroke in African American patients with a history of unstable angina or myocardial infarction.

Phase:

Phase 3

Details

Lead Sponsor:

deCODE genetics

Collaborators:

Duke University
Henry Ford Health System

Treatments:

2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid